natriuretic-peptide--c-type and Cardiotoxicity

natriuretic-peptide--c-type has been researched along with Cardiotoxicity* in 1 studies

Reviews

1 review(s) available for natriuretic-peptide--c-type and Cardiotoxicity

ArticleYear
[MODERN ASPECTS OF DIAGNOSIS AND TREATMENT OF HEART FAILURE, AS A MANIFESTATION OF ANTHRACYCLINE CARDIOTOXICITY (REVIEW)].
    Georgian medical news, 2018, Issue:278

    This review is devoted to the urgent problem of cardiology and oncology - the cardiotoxicity of chemotherapy drugs - anthracyclines, which are considered to be one of the most cardiotoxic and cause a variety of cardiotoxic effects. The review also examines the diagnosis, treatment or preventive treatment of this pathology. The urgency of the problem is associated with the possibility of early or late manifestations of cardiotoxicity, manifestations of cardiotoxicity against the background of cross treatment, manifestations of cardiotoxicity against the background of various concomitant diseases. The review identified 9 main categories of cardiovascular complications during chemotherapeutic treatment and presents the types of cardiotoxicity caused by the use of anthracyclines. The issue of heart failure as a manifestation of anthracycline cardiotoxicity and the approaches to early diagnosis of cardiac insufficiency were examined in detail. The recommendations of the European Society of Medical Oncology (ESMO) (2012), the recommendations the European Society of Cardiology (ESC) in 2016 regarding the diagnosis and treatment of these patients are reviewed. An overview of the literature on the treatment and diagnosis of this category of patients is presented, especially with concomitant diseases. Examination of the patients, the timing of the initiation of therapy, preventive treatment, medication correction of heart failure, the doses, the combinations of chemotherapeutic drugs are issues that are recommended for the multidisciplinary team to successfully manage these patients.

    Topics: Anthracyclines; Antineoplastic Agents; Biomarkers; Cardiomyopathies; Cardiotonic Agents; Cardiotoxicity; Echocardiography; Elapid Venoms; Heart; Heart Failure; Humans; Ivabradine; Natriuretic Peptide, C-Type; Neoplasms; Survival Analysis; Trastuzumab; Trimetazidine; Troponin I

2018